Source link : https://www.newshealth.biz/health-news/frontline-mosunetuzumab-shows-high-response-rates-in-follicular-lymphoma/
At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive response rates with frontline mosunetuzumab (Lunsumio) in high-tumor-bulk follicular lymphoma, positioning the bispecific antibody as a potential alternative to chemotherapy-based regimens. In this second of four exclusive episodes, MedPage Today brought together three expert leaders in the field, […]
Author : News Health
Publish date : 2024-12-26 14:00:00
Copyright for syndicated content belongs to the linked Source.
inHealth